These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20493882)

  • 1. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation.
    Mileni M; Kamtekar S; Wood DC; Benson TE; Cravatt BF; Stevens RC
    J Mol Biol; 2010 Jul; 400(4):743-54. PubMed ID: 20493882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties.
    Patricelli MP; Lovato MA; Cravatt BF
    Biochemistry; 1999 Aug; 38(31):9804-12. PubMed ID: 10433686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures.
    Mileni M; Garfunkle J; DeMartino JK; Cravatt BF; Boger DL; Stevens RC
    J Am Chem Soc; 2009 Aug; 131(30):10497-506. PubMed ID: 19722626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonempirical energetic analysis of reactivity and covalent inhibition of fatty acid amide hydrolase.
    Chudyk EI; Dyguda-Kazimierowicz E; Langner KM; Sokalski WA; Lodola A; Mor M; Sirirak J; Mulholland AJ
    J Phys Chem B; 2013 Jun; 117(22):6656-66. PubMed ID: 23654226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
    Ahn K; Johnson DS; Fitzgerald LR; Liimatta M; Arendse A; Stevenson T; Lund ET; Nugent RA; Nomanbhoy TK; Alexander JP; Cravatt BF
    Biochemistry; 2007 Nov; 46(45):13019-30. PubMed ID: 17949010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors.
    Lodola A; Capoferri L; Rivara S; Tarzia G; Piomelli D; Mulholland A; Mor M
    J Med Chem; 2013 Mar; 56(6):2500-12. PubMed ID: 23425199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.
    Ahn K; Johnson DS; Mileni M; Beidler D; Long JZ; McKinney MK; Weerapana E; Sadagopan N; Liimatta M; Smith SE; Lazerwith S; Stiff C; Kamtekar S; Bhattacharya K; Zhang Y; Swaney S; Van Becelaere K; Stevens RC; Cravatt BF
    Chem Biol; 2009 Apr; 16(4):411-20. PubMed ID: 19389627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes.
    Alexander JP; Cravatt BF
    Chem Biol; 2005 Nov; 12(11):1179-87. PubMed ID: 16298297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxime carbamate--discovery of a series of novel FAAH inhibitors.
    Sit SY; Conway CM; Xie K; Bertekap R; Bourin C; Burris KD
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1272-7. PubMed ID: 20036536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ω-Imidazolyl- and ω-Tetrazolylalkylcarbamates as Inhibitors of Fatty Acid Amide Hydrolase: Biological Activity and in vitro Metabolic Stability.
    Terwege T; Hanekamp W; Garzinsky D; König S; Koch O; Lehr M
    ChemMedChem; 2016 Feb; 11(4):429-43. PubMed ID: 26732805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
    Tarzia G; Duranti A; Gatti G; Piersanti G; Tontini A; Rivara S; Lodola A; Plazzi PV; Mor M; Kathuria S; Piomelli D
    ChemMedChem; 2006 Jan; 1(1):130-9. PubMed ID: 16892344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues.
    Clapper JR; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
    Pharmacol Res; 2006 Nov; 54(5):341-4. PubMed ID: 16935521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of fatty acid amide hydrolase with [(18)F]DOPP in nonhuman primates.
    Rotstein BH; Wey HY; Shoup TM; Wilson AA; Liang SH; Hooker JM; Vasdev N
    Mol Pharm; 2014 Nov; 11(11):3832-8. PubMed ID: 25004399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability.
    Vacondio F; Silva C; Lodola A; Fioni A; Rivara S; Duranti A; Tontini A; Sanchini S; Clapper JR; Piomelli D; Mor M; Tarzia G
    ChemMedChem; 2009 Sep; 4(9):1495-504. PubMed ID: 19554599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
    Slivicki RA; Xu Z; Mali SS; Hohmann AG
    Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
    Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
    Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
    Myllymäki MJ; Saario SM; Kataja AO; Castillo-Melendez JA; Nevalainen T; Juvonen RO; Järvinen T; Koskinen AM
    J Med Chem; 2007 Aug; 50(17):4236-42. PubMed ID: 17665899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).
    Piomelli D; Tarzia G; Duranti A; Tontini A; Mor M; Compton TR; Dasse O; Monaghan EP; Parrott JA; Putman D
    CNS Drug Rev; 2006; 12(1):21-38. PubMed ID: 16834756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
    Korhonen J; Kuusisto A; van Bruchem J; Patel JZ; Laitinen T; Navia-Paldanius D; Laitinen JT; Savinainen JR; Parkkari T; Nevalainen TJ
    Bioorg Med Chem; 2014 Dec; 22(23):6694-6705. PubMed ID: 25282655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice.
    Hoyer FF; Khoury M; Slomka H; Kebschull M; Lerner R; Lutz B; Schott H; Lütjohann D; Wojtalla A; Becker A; Zimmer A; Nickenig G
    J Mol Cell Cardiol; 2014 Jan; 66():126-32. PubMed ID: 24286707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.